Nature Communications (Aug 2021)
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
- S. Y. Cindy Yang,
- Scott C. Lien,
- Ben X. Wang,
- Derek L. Clouthier,
- Youstina Hanna,
- Iulia Cirlan,
- Kelsey Zhu,
- Jeffrey P. Bruce,
- Samah El Ghamrasni,
- Marco A. J. Iafolla,
- Marc Oliva,
- Aaron R. Hansen,
- Anna Spreafico,
- Philippe L. Bedard,
- Stephanie Lheureux,
- Albiruni Razak,
- Vanessa Speers,
- Hal K. Berman,
- Alexey Aleshin,
- Benjamin Haibe-Kains,
- David G. Brooks,
- Tracy L. McGaha,
- Marcus O. Butler,
- Scott V. Bratman,
- Pamela S. Ohashi,
- Lillian L. Siu,
- Trevor J. Pugh
Affiliations
- S. Y. Cindy Yang
- Department of Medical Biophysics, University of Toronto
- Scott C. Lien
- Department of Immunology, University of Toronto
- Ben X. Wang
- Princess Margaret Cancer Centre, University Health Network
- Derek L. Clouthier
- Princess Margaret Cancer Centre, University Health Network
- Youstina Hanna
- Princess Margaret Cancer Centre, University Health Network
- Iulia Cirlan
- Princess Margaret Cancer Centre, University Health Network
- Kelsey Zhu
- Princess Margaret Cancer Centre, University Health Network
- Jeffrey P. Bruce
- Princess Margaret Cancer Centre, University Health Network
- Samah El Ghamrasni
- Princess Margaret Cancer Centre, University Health Network
- Marco A. J. Iafolla
- Princess Margaret Cancer Centre, University Health Network
- Marc Oliva
- Princess Margaret Cancer Centre, University Health Network
- Aaron R. Hansen
- Princess Margaret Cancer Centre, University Health Network
- Anna Spreafico
- Princess Margaret Cancer Centre, University Health Network
- Philippe L. Bedard
- Princess Margaret Cancer Centre, University Health Network
- Stephanie Lheureux
- Princess Margaret Cancer Centre, University Health Network
- Albiruni Razak
- Princess Margaret Cancer Centre, University Health Network
- Vanessa Speers
- Princess Margaret Cancer Centre, University Health Network
- Hal K. Berman
- Princess Margaret Cancer Centre, University Health Network
- Alexey Aleshin
- Natera, Inc.
- Benjamin Haibe-Kains
- Department of Medical Biophysics, University of Toronto
- David G. Brooks
- Department of Immunology, University of Toronto
- Tracy L. McGaha
- Department of Immunology, University of Toronto
- Marcus O. Butler
- Department of Immunology, University of Toronto
- Scott V. Bratman
- Department of Medical Biophysics, University of Toronto
- Pamela S. Ohashi
- Department of Immunology, University of Toronto
- Lillian L. Siu
- Princess Margaret Cancer Centre, University Health Network
- Trevor J. Pugh
- Department of Medical Biophysics, University of Toronto
- DOI
- https://doi.org/10.1038/s41467-021-25432-7
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 15
Abstract
Although circulating tumour DNA (ctDNA) can predict immune checkpoint blockade (ICB) responses, its association with tumour biomarkers remains unknown. Here, the authors use ctDNA to inform exome and transcriptome profiling of >100 patients with 30 cancer types on a single clinical ICB trial and identify tumour microenvironment features associated with response.
